Immunoregulation in Multiple Sclerosis: Pathogenesis and Therapeutic Implications
1Department of Clinical Immunology, Hospital Clínico San Carlos, Madrid, Spain
2Inserm/Université U 1013, Hôpital Necker - Enfants Malades, Paris, France
3Department of Immunology, Germans Trias i Pujol University Hospital, Barcelona, Spain
Immunoregulation in Multiple Sclerosis: Pathogenesis and Therapeutic Implications
Description
After trauma, multiple sclerosis (MS) represents the most common cause of neurological disability in young people, with a significant personal, social, and economic public health burden. MS is a chronic inflammatory demyelinating disease of the central nervous system, in which repeated episodes of autoimmune-mediated demyelination result in the formation of gliotic scar tissue plaques associated with varying degrees of axonal loss. Moreover, a defective immunoregulation has been demonstrated at different levels in MS, defect that can be partially restored by some therapies used for MS. A better knowledge of the interplaying factors that modulate the activation and/or function of immune cells will contribute to better understanding of the etiopathogenesis of MS and will enable the design of therapeutical strategies for individualized cell therapy. Potential topics include, but are not limited to:
- Recent advances in immunopathogenesis of MS
- Advances on immune targets for MS
- Sex dimorphism and immunoregulation
- Role of microbiota in MS
- Vitamin D as an immunomodulator for MS
- Immunoregulatory effects of MS therapies
- Recent developments of therapies based on immunopathophysiology
- Towards a personalized therapy for MS
Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/jir/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/jir/imspt/ according to the following timetable: